— Know what they know.
Not Investment Advice

CNBX OTC

CNBX Pharmaceuticals Inc.
1W: +0.0% 1M: -0.0% 3M: -44.4% YTD: -75.0% 1Y: -71.4% 3Y: -99.5% 5Y: -100.0%
$0.00
-0.00 (-0.00%)
 
Weekly Expected Move ±4952.9%
$-0 $-0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 48 · $9251 mcap · 92M float · 13.76% daily turnover · Short 77% of daily vol

Balance Sheet Trends

Total Assets
$18K -41.3% ▼
5Y CAGR: -61.6%
Total Liabilities
$3M +0.1% ▲
5Y CAGR: +40.8%
Shareholders Equity
-$2M -0.7% ▼
Cash & Investments
$15K -42.8% ▼
5Y CAGR: -54.5%
Total Debt
$1M -7.6% ▼
Net Debt
$1M -6.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$1M$118K$130K$26K$15K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$1M$118K$130K$26K$15K
Net Receivables$204K$81K$95K$5K$3K
Inventory$0-$81K$0$0$0
Other Current Assets$0$0$95K$0$0
Total Current Assets$2M$198K$224K$31K$18K
Property, Plant & Equip.$643K$437K$275K$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$845K$176K$0$0$0
Other Non-Current Assets$0-$613K$0$0$0
Total Non-Current Assets$1M$613K$275K$0$0
Total Assets$3M$811K$499K$31K$18K
— Liabilities —
Accounts Payable$178K$461K$336K$41K$49K
Short-Term Debt$872K$2M$1M$1M$1M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$224K$224K$837K$0$1M
Total Current Liabilities$1M$2M$3M$3M$3M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$2$0$0$0
Total Non-Current Liabilities$0$2$0$0$0
Total Liabilities$1M$2M$3M$3M$3M
— Equity —
Common Stock$14K$124$2K$3K$55K
Retained Earnings-$17M-$21M-$24M-$25M-$25M
Accumulated OCI-$2M-$3M$0$0$0
Total Stockholders Equity$2M-$2M-$2M-$2M-$2M
Total Liabilities & Equity$3M$811K$499K$31K$18K
— Key Metrics —
Total Debt$872K$2M$1M$1M$1M
Net Debt-$515K$2M$1M$1M$1M
Total Investments$845K$176K$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms